Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010-2018

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jul 9

PMID 35804861

Authors

Florian Hucke

Matthias Pinter

Miriam Hucke

Simona Bota

Dajana Bolf

Monika Hackl

Markus Peck-Radosavljevic

Affiliations

Soon will be listed here.

Abstract

Using national registries, we investigated the epidemiological trends of hepatobiliary carcinomas in Austria between 2010 and 2018 and compared them to those reported for the periods of 1990-1999 and 2000-2009. In total, 12,577 patients diagnosed with hepatocellular carcinoma ( = 7146), intrahepatic cholangiocarcinoma ( = 1858), extrahepatic cholangiocarcinoma ( = 1649), gallbladder carcinoma ( = 1365), and ampullary carcinoma ( = 559), between 2010 and 2018, were included. The median overall survival of all patients was 9.0 months. The best median overall survival was observed in patients with ampullary carcinoma (28.5 months) and the worst median overall survival was observed in patients with intrahepatic carcinoma (5.6 months). The overall survival significantly improved in all entities over the period 2010-2018 as compared with over the periods of 2000-2009 and 1990-1999. Age-adjusted incidence and mortality rates remained stable for most entities in both, men and women; only in gallbladder carcinoma, the incidence and mortality rates significantly decreased in women, whereas, in men, the incidence rates remained stable and mortality rates showed a decreasing trend. We showed that age-adjusted incidence and mortality rates were stable in most entities, except in gallbladder carcinoma. The overall survival improved in almost all entities as compared with those during 1990-2009.

Citing Articles

Changes in the Epidemiology of Hepatocellular Carcinoma in Carinthia, Austria, 2012-2023.

Hucke F, Emmer H, Emmer R, Hucke M, Bota S, Furstner M Cancers (Basel). 2023; 15(21).

PMID: 37958389 PMC: 10649038. DOI: 10.3390/cancers15215215.

Impact of particle size of multivesicular liposomes on the embolic and therapeutic effects in rabbit VX2 liver tumor.

Tang H, Cao C, Zhang G, Sun Z Drug Deliv. 2023; 30(1):1-16.

PMID: 36644796 PMC: 9987747. DOI: 10.1080/10717544.2022.2157519.

Trends in Liver Cancer Incidence and Survival in Italy by Histologic Type, 2003-2017.

Mancini S, Bucchi L, Zamagni F, Guzzinati S, Dal Maso L, Rugge M Cancers (Basel). 2022; 14(24).

PMID: 36551647 PMC: 9777051. DOI: 10.3390/cancers14246162.

References

Singal A, Pillai A, Tiro J . Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014; 11(4):e1001624. PMC: 3972088. DOI: 10.1371/journal.pmed.1001624. View

Finn R, Cheng A . Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply. N Engl J Med. 2020; 383(7):695. DOI: 10.1056/NEJMc2021840. View

Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

Weaver A, Stafford R, Hale J, Denning D, Sanabria J . Geographical and Temporal Variation in the Incidence and Mortality of Hepato-Pancreato-Biliary Primary Malignancies:1990-2017. J Surg Res. 2019; 245:89-98. DOI: 10.1016/j.jss.2019.07.031. View

Bruix J, Qin S, Merle P, Granito A, Huang Y, Bodoky G . Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2016; 389(10064):56-66. DOI: 10.1016/S0140-6736(16)32453-9. View

Khan J, Ullah A, Matolo N, Waheed A, Nama N, Khan T . Klatskin Tumor in the Light of ICD-O-3: A Population-Based Clinical Outcome Study Involving 1,144 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (2001-2012). Cureus. 2021; 13(10):e18941. PMC: 8605626. DOI: 10.7759/cureus.18941. View

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

Clements O, Eliahoo J, Kim J, Taylor-Robinson S, Khan S . Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol. 2019; 72(1):95-103. DOI: 10.1016/j.jhep.2019.09.007. View

Valle J, Kelley R, Nervi B, Oh D, Zhu A . Biliary tract cancer. Lancet. 2021; 397(10272):428-444. DOI: 10.1016/S0140-6736(21)00153-7. View

10.

Saha S, Zhu A, Fuchs C, Brooks G . Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016; 21(5):594-9. PMC: 4861366. DOI: 10.1634/theoncologist.2015-0446. View

11.

Schaefer B, Viveiros A, Al-Zoairy R, Blach S, Brandon S, Razavi H . Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030. PLoS One. 2018; 13(7):e0200750. PMC: 6042769. DOI: 10.1371/journal.pone.0200750. View

12.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

13.

Banales J, Cardinale V, Carpino G, Marzioni M, Andersen J, Invernizzi P . Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-80. DOI: 10.1038/nrgastro.2016.51. View

14.

Pinter M, Peck-Radosavljevic M . Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018; 48(6):598-609. PMC: 6120553. DOI: 10.1111/apt.14913. View

15.

Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M . Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017; 67(6):1204-1212. DOI: 10.1016/j.jhep.2017.07.025. View

16.

Bruix J, Chan S, Galle P, Rimassa L, Sangro B . Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol. 2021; 75(4):960-974. DOI: 10.1016/j.jhep.2021.07.004. View

17.

Rizzo A, Dadduzio V, Lombardi L, Ricci A, Gadaleta-Caldarola G . Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges. Curr Oncol. 2021; 28(5):3393-3402. PMC: 8482111. DOI: 10.3390/curroncol28050293. View

18.

Pinter M, Hucke F, Zielonke N, Waldhor T, Trauner M, Peck-Radosavljevic M . Incidence and mortality trends for biliary tract cancers in Austria. Liver Int. 2013; 34(7):1102-8. DOI: 10.1111/liv.12325. View

19.

Anstee Q, Reeves H, Kotsiliti E, Govaere O, Heikenwalder M . From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019; 16(7):411-428. DOI: 10.1038/s41575-019-0145-7. View

20.

Kanwal F, Kramer J, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson P . Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018; 155(6):1828-1837.e2. PMC: 6279617. DOI: 10.1053/j.gastro.2018.08.024. View